142 related articles for article (PubMed ID: 26034081)
41. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors.
John CS; Vilner BJ; Geyer BC; Moody T; Bowen WD
Cancer Res; 1999 Sep; 59(18):4578-83. PubMed ID: 10493511
[TBL] [Abstract][Full Text] [Related]
42. The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.
Makvandi M; Lieberman BP; LeGeyt B; Hou C; Mankoff DA; Mach RH; Pryma DA
Nucl Med Biol; 2016 Jan; 43(1):35-41. PubMed ID: 26702785
[TBL] [Abstract][Full Text] [Related]
43. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands.
van Waarde A; Rybczynska AA; Ramakrishnan N; Ishiwata K; Elsinga PH; Dierckx RA
Curr Pharm Des; 2010; 16(31):3519-37. PubMed ID: 21050178
[TBL] [Abstract][Full Text] [Related]
44. Methyl substitution on the piperidine ring of N-[omega-(6-methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the sigma(1) receptor.
Berardi F; Ferorelli S; Abate C; Pedone MP; Colabufo NA; Contino M; Perrone R
J Med Chem; 2005 Dec; 48(26):8237-44. PubMed ID: 16366605
[TBL] [Abstract][Full Text] [Related]
45. NPC 16377, a potent and selective sigma-ligand. I. Receptor binding, neurochemical and neuroendocrine profile.
Karbon EW; Abreu ME; Erickson RH; Kaiser C; Natalie KJ; Clissold DB; Borosky S; Bailey M; Martin LA; Pontecorvo MJ
J Pharmacol Exp Ther; 1993 May; 265(2):866-75. PubMed ID: 8388461
[TBL] [Abstract][Full Text] [Related]
46. Investigation of σ receptors agonist/antagonist activity through N-(6-methoxytetralin-1-yl)- and N-(6-methoxynaphthalen-1-yl)alkyl derivatives of polymethylpiperidines.
Niso M; Abate C; Ferorelli S; Cassano G; Gasparre G; Perrone R; Berardi F
Bioorg Med Chem; 2013 Apr; 21(7):1865-9. PubMed ID: 23415062
[TBL] [Abstract][Full Text] [Related]
47. sigma-1 receptors protect RGC-5 cells from apoptosis by regulating intracellular calcium, Bax levels, and caspase-3 activation.
Tchedre KT; Yorio T
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2577-88. PubMed ID: 18296662
[TBL] [Abstract][Full Text] [Related]
48. Potential applications for sigma receptor ligands in cancer diagnosis and therapy.
van Waarde A; Rybczynska AA; Ramakrishnan NK; Ishiwata K; Elsinga PH; Dierckx RA
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2703-14. PubMed ID: 25173780
[TBL] [Abstract][Full Text] [Related]
49. Bicycloheptylamine-Doxorubicin Conjugate: Synthesis and Anticancer Activities in σ2 Receptor-Expressing Cell Lines.
Alamri MA; Ates-Alagoz Z; Adejare A
Med Chem; 2020; 16(2):192-201. PubMed ID: 30827254
[TBL] [Abstract][Full Text] [Related]
50. Novel Sigma-1 receptor antagonists: from opioids to small molecules: what is new?
Arena E; Dichiara M; Floresta G; Parenti C; Marrazzo A; Pittalà V; Amata E; Prezzavento O
Future Med Chem; 2018 Jan; 10(2):231-256. PubMed ID: 29185346
[TBL] [Abstract][Full Text] [Related]
51. [3H]1-(cyclopropylmethyl)-4-(2-(4-fluorophenyl)-2-oxoethyl) piperidine HBr (DuP 734). A selective ligand for sigma receptors in mouse brain in vivo.
Watanabe M; Rominger D; Hurt SD; De Souza EB; Tam SW
J Pharmacol Exp Ther; 1993 Sep; 266(3):1541-8. PubMed ID: 8371156
[TBL] [Abstract][Full Text] [Related]
52. σ-1 Receptor agonist SKF10047 inhibits glutamate release in rat cerebral cortex nerve endings.
Lu CW; Lin TY; Wang CC; Wang SJ
J Pharmacol Exp Ther; 2012 May; 341(2):532-42. PubMed ID: 22357973
[TBL] [Abstract][Full Text] [Related]
53. Biochemical Pharmacology of the Sigma-1 Receptor.
Chu UB; Ruoho AE
Mol Pharmacol; 2016 Jan; 89(1):142-53. PubMed ID: 26560551
[TBL] [Abstract][Full Text] [Related]
54. Dancing of the second aromatic residue around the 6,8-diazabicyclo[3.2.2]nonane framework: influence on sigma receptor affinity and cytotoxicity.
Holl R; Schepmann D; Fröhlich R; Grünert R; Bednarski PJ; Wünsch B
J Med Chem; 2009 Apr; 52(7):2126-37. PubMed ID: 19243173
[TBL] [Abstract][Full Text] [Related]
55. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
[TBL] [Abstract][Full Text] [Related]
56. Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands.
Zampieri D; Vio L; Fermeglia M; Pricl S; Wünsch B; Schepmann D; Romano M; Mamolo MG; Laurini E
Eur J Med Chem; 2016 Oct; 121():712-726. PubMed ID: 27366902
[TBL] [Abstract][Full Text] [Related]
57. 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs.
Mégalizzi V; Mathieu V; Mijatovic T; Gailly P; Debeir O; De Neve N; Van Damme M; Bontempi G; Haibe-Kains B; Decaestecker C; Kondo Y; Kiss R; Lefranc F
Neoplasia; 2007 May; 9(5):358-69. PubMed ID: 17534441
[TBL] [Abstract][Full Text] [Related]
58. Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo.
Intagliata S; Sharma A; King TI; Mesangeau C; Seminerio M; Chin FT; Wilson LL; Matsumoto RR; McLaughlin JP; Avery BA; McCurdy CR
AAPS J; 2020 Jul; 22(5):94. PubMed ID: 32691179
[TBL] [Abstract][Full Text] [Related]
59. The pharmacology of sigma-1 receptors.
Maurice T; Su TP
Pharmacol Ther; 2009 Nov; 124(2):195-206. PubMed ID: 19619582
[TBL] [Abstract][Full Text] [Related]
60. Novel sigma binding site ligands as inhibitors of cell proliferation in breast cancer.
Barbieri F; Sparatore A; Alama A; Novelli F; Bruzzo C; Sparatore F
Oncol Res; 2003; 13(11):455-61. PubMed ID: 12812359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
